All Pharma News
Johnson & Johnson Completes Acquisition of Ambrx

Johnson & Johnson Completes Acquisition of Ambrx
BUSINESSWIRE
07 Mar 2024
Share Share
J&J sees ‘opportunities’ in neuro and immunology post-Ambrx buy

J&J sees ‘opportunities’ in neuro and immunology post-Ambrx buy
FIERCE BIOTECH
23 Jan 2024
Share Share
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion

J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
CNBC
09 Jan 2024
Share Share
Ambrx Announces Sale to Johnson & Johnson

Ambrx Announces Sale to Johnson & Johnson
GLOBENEWSWIRE
08 Jan 2024
Share Share
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50

Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50
GLOBENEWSWIRE
23 Oct 2023
Share Share
Ambrx`s `reset` arrives at the last line of prostate cancer

Ambrx`s `reset` arrives at the last line of prostate cancer
Annalee Armstrong FIERCE BIOTECH
22 Oct 2023
Share Share
Ambrx Biopharma files $300M mixed securities shelf

Ambrx Biopharma files $300M mixed securities shelf
SEEKING ALPHA
18 Oct 2023
Share Share
Ambrx Provides Safety and Efficacy Data from Phase 1/2 APEX-01 Trial of ARX517

Ambrx Provides Safety and Efficacy Data from Phase 1/2 APEX-01 Trial of ARX517
GLOBENEWSWIRE
16 Oct 2023
Share Share
ESMO 2023 Abstracts Available Here

ESMO 2023 Abstracts Available Here
PRESS RELEASE
15 Oct 2023
Share Share
Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023

Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023
GLOBENEWSWIRE
26 Sep 2023
Share Share